81. Tokyo Medical University Genetics Gene Therapy Problems Animations of Problems in gene therapy one gene is mutated and the other is inserted and mutated (7K). genes that are mutated don t work but the http://www.tokyo-med.ac.jp/genet/gpr-e.htm

Tokyo Medical University Department of Paediatircs Genetics Study Group Hironao NUMABE, M.D. E-mail: hnumabe@tokyo-med.ac.jp Japanese Page is Here. Animations of Problems in Gene Therapy: insertion error (7K) activated oncogene by regulating gene (11K) gene is inserted into normal gene (7K) one gene is mutated but the other works (9K) one gene is mutated and the other is inserted and mutated (7K) genes that are mutated don't work but the inserted gene works (9K) Tokyo Medical University Home Pediatrics Home Genetics Home

82. ACS :: Gene Therapy: Questions & Answers gene therapy Questions Answers. Introduction What Is a Gene? What Is gene therapy? How Does gene therapy Work? When Will gene therapy Be Available? http://www.cancer.org/docroot/ETO/content/ETO_1_3X_Gene_Therapy_Questions_and_An

Home Community Get Involved Donate ... Site Index GetRandomImage("headerImage", "jpg", 121, 77, 30); My Planner Register Sign In Making Treatment Decisions ... I Want to Help Help in the fight against cancer. Donate and volunteer. It's easy and fun! Learn more Introduction What Is a Gene? What Is Gene Therapy? ... Email this Page Also in this area Antiangiogenesis Treatment Welcome message Photodynamic Therapy Cord Blood Transplantation ... Building a Support Network createContextNavLink('', '/asp/login/logreg.asp?navToScreen=reg_0', '', '/docroot/ETO/content/ETO_1_3X_Gene_Therapy_Questions_and_Answers.asp', '', ''); Not registered yet? Register now or see reasons to register Help About ACS ACS Gift Shop ... Press Room All content and works posted on this website are owned and

83. Salon.com Health | Gene Therapy R.I.P.? When the country s biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious http://archive.salon.com/health/feature/2000/06/01/gene_therapy/index.html

Apache::Oas::ad('TopLeft') Apache::Oas::ad('Top') Apache::Oas::ad('TopRight') Search About Salon Table Talk Newsletters ... Search Articles by date All of Salon.com Books Business Comics ... Table Talk [Freewheeling Salon forums] On pins and needles? Maybe acupuncture is the answer. Tame your tummy! Which exercises are best for flatter abs? Living mementos Our scars are one-of-a-kind souvenirs. Posts of the week The Well [Pioneering members-only discussions] Geaux Opelousas! A former Berkeleyite takes on a new lifestyle in Louisiana. Sound Off E-mail Salon Send us a Letter to the Editor Today's letters Newsletter Sign up to receive free e-mail updates from Salon now in 12 different varieties! Downloads Get Salon.com on your PDA Salon.com headlines from More ways to get Salon Gene therapy R.I.P.? When the country's biggest gene therapy institute was ordered to stop testing on humans last week, the action marked the end of an era fraught with dubious claims to success and a mess of unreported adverse effects. By Tabitha M. Powledge In September, Jesse Gelsinger, a teenage patient undergoing experimental gene therapy for a rare genetic disorder, died at the Institute for Human Gene Therapy at the University of Pennsylvania. People die during experimental treatments all the time because they are usually terribly sick. But Jesse was not particularly ill, and his father says the researchers played up the potential benefits of the study and played down the potential risks. The researchers deny this, so Jesse's father is talking about filing suit.

84. Gene Therapy Study Likely To Resume - International Herald Tribune NEW YORK U.S. regulators have given permission for a company to resume a gene therapy study in which a woman died, the company was expected to announce http://www.iht.com/articles/2007/11/26/america/gene.php

Americas iht.com Business Culture ... Search Gene therapy study likely to resume By Andrew Pollack Published: November 26, 2007 document.writeln(''); E-Mail Article Listen to Article Printer-Friendly 3-Column Format Translate Share Article Text Size NEW YORK U.S. regulators have given permission for a company to resume a gene therapy study in which a woman died, the company was expected to announce Monday. The death had threatened to be another black eye for gene therapy, a field that has not had much success in treating disease and that suffered a setback in 1999 when a teenager died while participating in a clinical trial at the University of Pennsylvania. A spokeswoman for the Food and Drug Administration said it could not comment on its communications with companies involving drugs in clinical trials. The agency halted the trial in July after the death of the woman, Jolee Mohr, 36, of Taylorville, Illinois. Today in Americas U.S. candidates get set for 2 crucial primaries Brazil announces new measures to fight Amazon deforestation Author of interrogation memos renominated for top post Mohr died three weeks after receiving her second injection of a gene meant to reduce inflammation and treat her rheumatoid arthritis. The direct cause of her death appeared to be a fungal infection, histoplasmosis, according to testimony at a review of her case in September by an advisory committee to the National Institutes of Health. But the committee said it was too early to conclude that the gene therapy had not been a factor.

85. Gene Therapy To Repair Injured Tendon-Health/Science-The Times Of LONDON A research team from University of Rochester Medical Centre is developing freezedried implants loaded with gene therapy solution that can help http://timesofindia.indiatimes.com/HealthScience/Gene_therapy_to_repair_injured_

var a=2696651 var secid=-2128672765 var ttrendlogmostviewed=1; var doweshowbellyad=1; Indiatimes l My Mail l Make TOI your home page l ePaper l Headlines l Archives Health/Science Times of India Indiatimes Web Advanced Search Home Cities India ... Classifieds Gene therapy to repair injured tendon 13 Jan 2008, 1522 hrs IST ANI Print Save EMail Write to Editor LONDON: A research team from University of Rochester Medical Centre is developing freeze-dried implants loaded with gene therapy solution that can help repair injured and difficult-to-treat tendons in patients with orthopaedic injury. The researchers said that the new technique of using the so-called allografts inserted with therapeutic genes offers orthopaedic surgeons a better approach in treating common sports injuries such as anterior cruciate ligaments and rotator cuffs. The study was conducted in a mouse model designed to resemble hard-to-repair flexor tendons in human hands. Tendons are elastic cords that anchor muscle to bone and enable flexing muscle to move limbs. In many standard repair attempts, surgeons implant an autograft, a piece of tendon from elsewhere in the same patient. Along with requiring patients to sacrifice tendon, the problem with 'live' autografts is that both the graft and the graft site 'know' they have been injured. That signals immune cells and chemicals to rush into the graft site, seeking to fight infection. Unfortunately, those same processes cause inflammation and scarring, which in turn cause implanted tendon to stick to the joint. To work properly, the tendon must be free to glide across the joint. Tendon adhesions, a longstanding post-surgical problem, cause pain and permanently limit range of motion.

86. 594 GENE THERAPY Your browser may not have a PDF reader available. Google recommends visiting our text version of this document. http://www.blackwell-synergy.com/doi/pdf/10.1046/j.1365-2516.2002.00025.x

87. The Scientist : Gene Therapy Trial On Hold As the US Food and Drug Administration prepares to investigate the death of a patient in a phase I/II gene therapy trial for inflammatory arthritis, http://www.the-scientist.com/news/home/53453/

Please Login or Register Science News RSS Feed NewsBlogs Podcasts Supplements ... Autoimmunity Survey Series Best Places to Work Vote Now! Lab Web Site and Video Awards The Scientist Daily Science headlines delivered daily. Register today. For Advertisers Advertise with Us Contact Ad Team 2008 Media Kit 1 comment ... De.licio.us bookmark digg_skin = 'compact'; Email to a friend Close Window By Chandra Shekhar NEWS Gene therapy trial on hold Researchers say viral vector unlikely to be culprit in patient's death [Published 31st July 2007 04:57 PM GMT] As the US Food and Drug Administration prepares to investigate the death of a patient in a phase I/II gene therapy trial for inflammatory arthritis, researchers in the field say the treatment's delivery vector, an adeno-associated virus (AAV), was unlikely to be the culprit. "Vectors in this class have been used on hundreds of patients over the last 12 years, and are not associated with acute toxicity," said Terence Flotte of the University of Massachusetts Medical School in Worcester. Flotte has been a principal investigator in several clinical trials of AAV-based gene therapy, but is not associated with the trial in question. "I've never seen anything like this," he told The Scientist . "Whatever this is, it's unusual."

88. Child Gets Leukaemia After Gene Therapy | Science | The Guardian A threeyear-old boy has developed leukaemia as a result of gene therapy, Great Ormond Street children s hospital in London said yesterday. http://www.guardian.co.uk/science/2007/dec/19/cancer.medicalresearch

Jump to content [s] Jump to site navigation [0] Jump to search [4] Terms and conditions [8] ... Back to online version Search: guardian.co.uk Science Web Home Science news Comment Podcasts ... Environment Child gets leukaemia after gene therapy Sarah Boseley , health editor The Guardian Wednesday December 19 2007 Contact us Close Contact the Science editor science@guardian.co.uk Report errors or inaccuracies: reader@guardian.co.uk Letters for publication should be sent to: letters@guardian.co.uk If you need help using the site: userhelp@guardian.co.uk Call the main Guardian and Observer switchboard: Advertising guide License/buy our content About this article Close This article appeared in the Guardian on Wednesday December 19 2007 on p14 of the UK news section. It was last updated at 14:46 on January 15 2008. A three-year-old boy has developed leukaemia as a result of gene therapy, Great Ormond Street children's hospital in London said yesterday. The boy, who was born without an immune system, was given gene therapy as a baby to save his life.

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 5     81-88 of 88    Back | 1  | 2  | 3  | 4  | 5